Peptide Therapy: What the Phrase Denotes, and the Three Gates a Compounded Peptide Has to Pass

"Peptide therapy" is searched roughly 17,700 times a month in the United States, plus another 9,100 for "peptide therapy near me". It is a commercial category, not a drug and not a diagnosis, and the single most useful thing to know about it is that the phrase means two unrelated things depending on who is using it. This page separates them, then sets out the statutory test that decides what a compounding pharmacy may lawfully supply, which is the part the marketing does not cover. It is documentary journalism and contains no clinical guidance, per our editorial standards.

Two meanings, one phrase

A PubMed search for "peptide therapy"[tiab] on 2026-09-18 returns 312 records. Classified:

In medicine the phrase principally denotes peptide cancer vaccines and peptide receptor radionuclide therapy, a well-established treatment for neuroendocrine tumours in which a peptide carries a radioisotope to a receptor. Neither has anything to do with recovery, lean mass or ageing.

The consumer meaning — injectables ordered through a clinic or a telehealth intake form — accounts for a handful of records under that name. This is not evidence that the individual compounds are unstudied; several have their own literatures, counted compound by compound in our growth hormone secretagogue coverage and the entries beneath it. It is evidence that the umbrella term is a marketing category, and searching for research under it returns somebody else's field.

The three gates

The question a reader actually has is whether a clinic can lawfully supply these compounds. The answer is in one sentence of the Federal Food, Drug, and Cosmetic Act.

Section 503A governs compounding by a licensed pharmacist or physician. A drug may be compounded from a bulk drug substance only where the substance, in the statute's own words at 21 U.S.C. 353a(b)(1)(A)(i):

1. complies with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists; or
2. if no monograph exists, is a component of a drug approved by the Secretary; or
3. if neither applies, appears on a list developed by the Secretary through regulation.

Three gates, and a substance needs only one. The statute adds two further conditions that are rarely mentioned: the bulk substance must be made by an FDA-registered establishment, and must arrive with a valid certificate of analysis.

A peptide with no monograph, which is not a component of any approved drug, and which is not on FDA's list, passes none of the three. That is not a grey area in the drafting — it is the drafting.

FDA's two lists, and the difference between them

Whether a substance is "on the list" is where the detail sits, because FDA publishes two records and they mean different things.

Category 2 — nominated, and identified as presenting significant safety risks. These entries carry a date and a stated reason. The peptide and secretagogue entries:

FDA's stated reason for the peptide entries is consistent: a risk of immunogenicity for certain routes of administration, from aggregation and peptide-related impurities, together with difficulty characterising the active ingredient. For ibutamoren the reason is different and specific — the potential for congestive heart failure in certain patients.

Nominated but withdrawn. A separate table on the same FDA page lists substances whose nominations were withdrawn. It runs to 17 entries, and it reads like a clinic menu: AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, injectable GHK-Cu, ipamorelin acetate, KPV, PEG-MGF, melanotan II, MOTS-c, selank acetate, semax, thymosin-alpha 1, and thymosin beta-4 fragment — the fragment sold as TB-500.

The distinction matters and is routinely blurred. A withdrawn nomination is not a finding that a substance is dangerous. It is the absence of an entry: the nomination was pulled, so the substance never reached the list, so gate three stays shut. FDA's own wording on several of them is that it has not identified any human exposure data — a statement about missing evidence, not about established harm.

Either way the practical effect is the same. For a substance with no monograph and no approved-drug parent, both lists lead away from lawful compounding under 503A.

What is approved, and what the approvals say

A few peptides in this space are approved drugs, and their labels are more restrictive than the category implies.

• Tesamorelin is approved for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and both of its current labels state under Limitations of Use that it "is not indicated for weight loss management as it has a weight neutral effect" — the regulator writing out the use it is most often borrowed for, and saying why.
• Sermorelin held two FDA approvals, in 1990 and 1997. Both were discontinued. FDA's record carries the determination that neither was withdrawn for reasons of safety or effectiveness, which disposes of the claim that it was banned.
• CJC-1295 has one ClinicalTrials.gov registration, terminated. Ipamorelin has two.

Approval attaches to a drug for an indication. There is no such thing as an approved category, which is why the sentence "peptide therapy is FDA approved" cannot be evaluated as written.

The endpoint nobody registered

One census is worth stating on its own, because it cuts against the marketing directly.

Across 41 ClinicalTrials.gov registrations of tesamorelin, ipamorelin, sermorelin, BPC-157 and ibutamoren, the number registering testosterone as an outcome measure is zero. Prostate: zero. Sperm or fertility: zero.

The registry is reachable for this set — twelve of the same registrations carry a fat outcome and six carry a growth hormone outcome — so the zeros are not a search artefact. They mean the male hormonal endpoints these compounds are marketed against have not been registered as outcomes in a single trial of them.

What this page does not say

It does not say the compounds do nothing; that is a question for the evidence on each one, and this site grades it compound by compound. It does not say every clinic operates outside the law; some prescribe approved drugs for approved indications, which is ordinary medicine. And it takes no position on whether the statute should read as it does.

What it does say is that "peptide therapy" is a name for a commercial arrangement, and the arrangement has a legal test that is short, public and checkable — and that the most-advertised compounds in the category fail all three of its gates.

For what the same compounds mean inside sport's rulebooks rather than the drug rulebook, see are peptides legal for athletes and peptides and drug testing. For the evidence behind the muscle claims, see peptides for muscle growth.

Key figures

• 3 — the statutory gates at 21 U.S.C. 353a(b)(1)(A)(i); a bulk substance needs one.
• 5 — peptides or secretagogues on FDA's Category 2 list.
• 17 — substances on FDA's withdrawn-nomination record, including BPC-157, CJC-1295 and TB-500.
• 312 — PubMed records for the phrase, of which 107 concern cancer and 9 name any of the four clinic compounds.
• 0 — registrations of five leading compounds with a testosterone, prostate, sperm or fertility outcome, out of 41.

This page reports statutory text, FDA lists and registry counts. It contains no recommendation, and decisions about treatment belong with a clinician.

Sources

• 21 U.S.C. § 353a, Pharmacy compounding — subsection (b)(1)(A), read in full 2026-09-18 — law.cornell.edu/uscode/text/21/353a
• U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks — Category 2 table and the record of withdrawn nominations; page content current as of 22 April 2026, read 2026-09-18 — fda.gov
• National Library of Medicine. PubMed — census of "peptide therapy"[tiab] and its subsets, run 2026-09-18 — pubmed.ncbi.nlm.nih.gov
• ClinicalTrials.gov API v2 — registration counts and outcome-measure searches for tesamorelin, ipamorelin, sermorelin, BPC-157 and ibutamoren, run 2026-09-18 — clinicaltrials.gov
• Theratechnologies Inc. EGRIFTA WR (tesamorelin) prescribing information, label revision 03/2025, and EGRIFTA SV (tesamorelin) prescribing information — Indications and Limitations of Use read in full via DailyMed 2026-09-18 — dailymed.nlm.nih.gov

All sources retrieved 2026-09-18. Registry and literature counts are as of that date.